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Abstract
Arming of oncolytic viruses with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown as a viable
approach to increase the antitumor efficacy in melanoma. However, melanoma cells may be partially or completely resistant to
TRAIL or develop TRAIL resistance, thus counteracting the antitumor efficiency of TRAIL-armed oncolytic viruses. Recently,
we found that TRAIL resistance in melanoma cells can be overcome by inhibition of antiapoptotic Bcl-2 protein myeloid cell
leukemia 1 (Mcl-1). Here, we investigated whether the cytotoxicity of AdV-TRAIL, an oncolytic adenovirus, which expresses
TRAIL after induction by doxycycline (Dox), can be improved in melanoma cells by silencing of Mcl-1. Two melanoma cell
lines, the TRAIL-resistant MeWo and the TRAIL-sensitive Mel-HO were investigated. Treatment of both cell lines with AdV-
TRAIL resulted in a decrease of cell viability, which was caused by an increase of apoptosis and necrosis. The proapoptotic
effects were dependent on induction of TRAIL by Dox and were more pronounced in Mel-HO than in MeWo cells. SiRNA-
mediated silencing of Mcl-1 resulted in a further significant decrease of cell viability and a further increase of apoptosis and
necrosis in AdV-TRAIL-infectedMeWo andMel-HO cells. However, while in absolute terms, the effects weremore pronounced
in Mel-HO cells, in relative terms, they were stronger in MeWo cells. These results show that silencing of Mcl-1 represents a
suitable approach to increase the cytotoxicity of a TRAIL-armed oncolytic adenovirus in melanoma cells.
Key messages
• Cytotoxicity of TRAIL-expressing adenovirus can be enhanced by silencing of Mcl-1.
• The effect occurs in TRAIL-sensitive and TRAIL-resistant melanoma cells.
• Increase of apoptosis is the main mechanism induced by Mcl-1 silencing.
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Introduction
The incidence of malignant melanoma, a highly aggressive
skin cancer, has been increasing over the past few decades.
Globally, each year, approximately 300,000 new patients are
diagnosed with cutaneous melanoma, which thus belongs to
the ten most common cancers in North America, Western
Europe, and Oceania [1, 2]. Severe chemotherapy resistance
and early dissemination of melanoma impeded effective ther-
apy for decades. Only recently, selective inhibitors for the
MAP kinases BRAF andMEK, as well as immune checkpoint
modulators, as antibodies for CTLA4, PD1, or PDL1, have
significantly improved melanoma therapy [3–5]. Although
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these new treatments significantly prolong overall survival of
patients with metastatic melanoma, no adequate therapy is
available yet able to cope with cancer recurrence and therapy
resistance [5].
Apoptosis deficiency plays a major role in therapy resistance
in cancers such as melanoma. Apoptosis can be induced via
intrinsic and extrinsic apoptosis pathways. The latter are induced
by death ligands as TRAIL and CD95L/Fas ligand [6, 7]. Death
ligands bind to cognate death receptors [8] which results in acti-
vation of proapoptotic initiator caspase-8 and caspase-10 [8, 9].
In the next step, initiator caspases proteolytically cleave and ac-
tivate effector caspases, such as caspase-3, caspase-6, and cas-
pase-7, which themselves cleave a large number of death sub-
strates to induce apoptosis [10]. Extrinsic apoptosis pathways
induced by TRAIL or CD95L/Fas ligand may be further linked
to the intrinsic apoptosis pathways via caspase-8-mediated pro-
cessing of the proapoptotic BH3-only protein Bid, which may
mediate activation of the multi-domain, proapoptotic Bcl-2 pro-
teins Bax and Bak. These proteins increase mitochondrial per-
meability, thus inducing the release of proapoptotic mitochondri-
al factors, such as cytochrome c and second mitochondria-
derived activator of caspases (Smac) [8]. Cytosolic cytochrome
c triggers formation of the apoptosome, a multiprotein complex
containing the adapter protein Apaf-1. Here, another initiator
caspase, caspase-9, is activated, which strengthens the activation
of effector caspase-3 [8]. As an antagonist of the cellular inhib-
itors of apoptosis proteins (cIAPs), Smac also drives effector
caspase activation [11].
Due to its central role in apoptosis induction, as well as the
fact that TRAIL induces apoptosis only in cancer cells, while
normal cells are largely unaffected [12], the therapeutic em-
ployment of TRAIL has come into focus of cancer therapy.
However, despite encouraging results observed in an experi-
mental setting, the efficiency of this approach in patients
remained only limited [13], most likely because cancer cells
may be resistant to TRAIL per se or rapidly acquire inducible
resistance upon TRAIL treatment [8, 14]. In melanoma cells,
direct caspase activation by death ligands via the extrinsic apo-
ptosis pathway appears less active. Thus, the mitochondrial
activation loop via caspase-8 and Bid seems to be of particular
importance [8]. However, the intrinsic apoptosis pathway is
strictly controlled by prosurvival antiapoptotic Bcl-2 proteins
and these proteins are often overexpressed in tumor cells and
contribute to tumorigenesis and drug resistance [15, 16]. Mcl-1
belongs to the antiapoptotic Bcl-2 proteins. Over the last few
years, this protein has received particular attention as a target for
cancer therapy due to the fact that it is often overexpressed in
cancer cells and that the MCL1 locus is one of the most fre-
quently amplified regions of the human genome across a wide
variety of cancers [17, 18]. Mcl-1 can heterodimerize and thus
antagonize the proapoptotic activity of a number of
proapoptotic Bcl-2 proteins, i.e., the BH3-only proteins Bim,
tBid, Puma, and Noxa [19] as well as the proapoptotic, multi-
domain proteins Bak and, to a lesser extent, Bax. Due to the
neutralization of a broad spectrum of proapoptotic Bcl-2 pro-
teins, Mcl-1 may compensate for the loss of other antiapoptotic
Bcl-2 proteins in tumor cells, suggesting it as a potential key
regulator of antiapoptotic control in cancer cells.
Oncolytic adenoviruses (oAdV) selectively replicate in tu-
mor cells, leading to their destruction [20]. Their safety was
demonstrated in various animal cancer models in vivo as well
as in clinical trials. However, clinical investigations revealed
that first-generation oAdV were not sufficient to significantly
alter the course of cancer progression in patients [21]. One
way to increase the efficacy of oAdV was achieved by arming
these viruses with cell death-promoting transgenes.
Particularly, transgenes targeting apoptosis pathways were
considered, and the proapoptotic death ligand TRAIL ap-
peared to be the most promising candidate. When expressed
from oAdV, TRAIL significantly increased the efficiency of
virotherapy, as shown in several in vivo studies [22, 23].
Previously, we have developed AdV-TRAIL (Fig. 1A), an
oAdV, which selectively expresses TRAIL and replicates in
melanoma cells [24]. The virus showed an increased oncolytic
activity in melanoma in vitro and in vivo resulting from
TRAIL-mediated induction of apoptosis. Nevertheless, our
investigations revealed that TRAIL resistance may limit the
oncolytic efficacy also of AdV-TRAIL [24].
Here, we show that the cytotoxicity of AdV-TRAIL can be
significantly enhanced in TRAIL-sensitive and TRAIL-resistant
melanoma cells by silencing of Mcl-1. Enhancement of apopto-
sis by Mcl-1 silencing was determined as a key mechanism
leading to increased cytotoxicity of AdV-TRAIL.
Methods
Cell culture
Origin of the four human melanoma cell lines used in this
study (MeWo, Mel-2a, SK-Mel-19 and Mel-HO) was de-
scribed previously [25]. All cell lines have significant tyrosi-
nase mRNA expression [25, 26]. Human embryonal kidney
(HEK-293) cells were used for adenovirus amplification and
quantification. All cell lines were cultivated in Dulbecco’s
modified Eagle’s medium (DMEM, 4.5 g/l glucose,
Biowest, Nuaillé, France), 10% fetal calf serum (c.c.pro,
Oberdorla, Germany) and 1% of each penicillin and strepto-
mycin (Biowest, Nuaillé, France) at 37 °C and 5% CO2.
Soluble TRAIL (Adipogen, San Diego, CA, USA) was added
to the cell culture in a concentration of 50 ng/ml.
Cell transfection with siRNA
Cells were reversely and transiently transfected with siRNA
using Lipofectamine RNAiMAX (Thermo Fisher Scientific,
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Waltham, MA USA), according to the manufacturer’s protocol.
For reverse transfection 15 pmol siRNA and 1 μl Lipofectamine
were added to 500 μl cell suspension (105 cells) prior to seeding
in a 24-well plate. The siRNA (siMcl-1) which enables efficient
silencing of Mcl-1 [27] 5 ′-AUAAUCUCCAGCGA
CUGCCdTdT-3′ and the control siRNA (siCon) [28] 5′-
ACGUGACACGUUCGGAGAAdTdT-3′ were described pre-
viously. SiCon does not match any sequence present in the viral
or human genome [28]. Both siRNAs were ordered from
Eurofins Genomics (Ebersberg, Germany).
Production of AdV-TRAIL and induction of TRAIL
expression
AdV-TRAIL [24] is a E1/E3-deleted oncolytic adenovirus
armed with TRAIL which is controlled by a Dox-inducible
promoter (Figure 1A). Melanoma cell-selective replication of
AdV-TRAIL is ensured by controlling an engineered adeno-
viral E1A protein lacking the retinoblastoma-binding domain
(E1AΔpRb) by a human tyrosinase promoter that has high se-
lectivity for melanoma cells [29]. AdV-TRAIL was
reamplified onHEK293 cells, purified by double CsCl density
gradient centrifugation and the viral titer determined by stan-
dard plaque assay on HEK293 cells. The expression of
TRAIL from AdV-TRAIL was induced by addition of Dox
(Sigma-Aldrich, Darmstadt, Germany) to the cell culture me-
dium at a concentration of 1 μg/ml. If the investigation period
was longer than 24 h, Dox was re-applied at the same concen-
tration after 24 h.
Determination of AdV-TRAIL titers
AdV-TRAIL-infected melanoma cells were lysed by three
freeze–thaw cycles and cell debris was removed by
Fig. 1 Resistance of certain melanoma cell lines to AdV-TRAIL treat-
ment. A Schematic overview of the regulation elements of AdV-TRAIL.
E1A lacking the retinoblastoma-binding domain (E1AΔpRb) is controlled
by a tyrosinase promoter which ensures a selective expression (a) and
subsequent viral replication (b) in melanoma cells. E1AΔpRb also slightly
transactivates the bi-directional doxycycline (Dox)-inducible Tight pro-
moter (c) leading to minimal expression of the reverse tetracycline
transactivator (rtTA) (d). In the presence of Dox, rtTA is able to bind to
the Tight promoter (e) and induces strong rtTA expression (f), resulting in
an activation loop. In parallel, activation of the Tight promoter in the
presence of Dox leads to TRAIL expression (g), which subsequently
induces apoptosis (h). In cells without tyrosinase promoter activity,
E1AΔpRb and TRAIL are not expressed. Adenoviral inverted terminal
repeats are labeled as 5′-ITR and 3′-ITR. B Cell viability of four melano-
ma cell lines after treatment with TRAIL and AdV-TRAIL. Cells were
either treated with soluble TRAIL (50 ng/ml) or transduced with AdV-
TRAIL (5 MOI). In the latter case, TRAIL expression was induced by
Dox as indicated. Cell viability was detected by calcein-AM staining 48 h
after transduction with AdV-TRAIL or treatment with soluble TRAIL,
respectively. The mean percentages of calcein-AM-positive cells (viable)
± SEM of three independent experiments are shown. Statistical signifi-
cance: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
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centrifugation at 6000×g for 10min. To determine the number
of infectious virus particles, confluent HEK293 cells, seeded
in 24-wells, were incubated with 200 μl of the supernatant for
2 h. In parallel, HEK293 cells were infected at a MOI of 10, 1,
0.1, and 0.01 of AdV-TRAIL. These samples were used to
generate a standard graph to calculate virus concentration of
the investigated samples. Infected cells were washed with
PBS to remove unbound virus and lysed in 100 μl PBS by
three freeze–thaw cycles. Following centrifugation at 6000×g
for 10 min, an aliquot of 5 μl was diluted 1:10 in PBS and
inactivated at 95 °C for 5 min. Subsequently, 1.5 μl of the
solution were used in a real-time PCR to determine the ade-
novirus copy number as previously described [30].
Determination of cell viability
Cells (105) were reversely transfected with 30 nM of
siCon or siMcl-1 and seeded in 24-well plates. After
48 h, the cells were incubated with soluble TRAIL
(50 ng/ml) or infected with AdV-TRAIL. Dox (1
μg/ml) was added, when TRAIL expression was
intended. Cell viability was determined by calcein-
acetoxymethyl (calcein-AM) staining at 24 h and 48 h
after transduction with AdV-TRAIL. For measurement
of cell viability, cells were harvested by trypsinization
and stained with 2.5 μg/ml calcein-AM (PromoCell,
Heidelberg, Germany) for 1 h at 37 °C. Subsequently,
the labeled cells were washed with PBS and the per-
centage of calcein-AM-positive cells measured by flow
cytomet ry (FL2H) wi th a FACS Cal ibur (BD
Biosciences, Bedford, MA, USA).
Cell killing assay
Cells (105) were reversely transfected with 30 nM of siCon or
siMcl-1 and seeded in 24-well plates. After 48 h, the cells were
infected with AdV-TRAIL at a MOI of 2 (Mel-HO) and 25
(MeWo). Dox (1 μg/ml) was added when TRAIL expression
was intended. Attached cells were stained at 24 h (Mel-HO)
and 48 h (MeWo) after transduction with AdV-TRAIL. For
staining, the medium was removed, and the cells were washed
with PBS. To fix the cells, 200 μl 10% trichloroacetic acid (Carl
Roth, Karlsruhe, Germany)was added for 10min. The cells were
washed twice with PBS and overlaid with 200 μl crystal violet
solution (0.1 % in 1 % EtOH, Carl Roth). After an incubation of
5 min, the cells were washed with PBS several times. The plate
was allowed to dry overnight and photographed.
Determination of apoptosis
Cell cycle analysis by propidium iodide labeling and quanti-
fication of apoptosis were performed as described previously
[31]. Cells grown and treated in 24-well plates were harvested
by trypsinization. The harvested cells were lysed in hypotonic
buffer and the isolated nuclei were stained for 1 h with 40
μg/ml propidium iodide (Sigma-Aldrich). Cells in different
cell cycle phases were quantified based on their DNA content
by flow cytometry (FL3A) with a FACS Calibur (BD
Biosciences).
Determination of necrosis
Necrosis was determined by measuring lactate dehydrogenase
(LDH) activity in cell culture supernatant using the
CyQUANT™ LDHCytotoxicity Assay according to the man-
ufacturer’s protocol (Thermo Fisher Scientific). Cells were
grown and treated in 24-well plates, as described above.
Western blot analysis
Protein extraction and western blot analysis were per-
formed as described previously [25]. Protein levels were
quantified using ImageJ and normalized to β-actin
levels. For detection of proteins in the supernatant, the
conditioned media and cell debris were separated by
centrifugation. The collected supernatant was subse-
quently concentrated using Amicon Ultra Centrifugal
Filters (UFC200324, Merck, Darmstadt, Germany) and
western blot analysis were performed. Primary antibod-
i e s u s e d we r e E 1A ( s c - 5 8 6 5 8 , S a n t a C r u z
Biotechnology, Dallas, TX, USA; diluted 1:1000),
TRAIL (3219, Cell Signaling Technology, Danvers,
MA, USA; diluted 1:1000), Mcl-1 (4572, Cell
Signaling; diluted 1:1000), caspase-8 (9746, Cell
Signaling, 1:1000), cleaved caspase-3 (9664, Cell
Signaling, 1:1000), cleaved caspase-9 (20750, Cell
Signaling, 1:1000), and β-actin (3700, Cell Signaling;
1 :1000) . As secondary ant ibodies horserad ish
peroxidase-labeled goat anti-rabbit and goat anti-mouse
immunoglobulins were used (Agilent Dako, Santa Clara,
CA, USA; diluted 1:5000). Proteins were detected using
Chemiluminescence HRP Reagent (Serva, Heidelberg,
Germany) and visualized by the ChemiDoc™ MP
Imaging System (Biorad, Feldkirchen, Germany).
Statistical analyses
All data was collected in duplicates or triplicates, in at least
three independent experiments. Mean values, SEMs, and sta-
tistical significancewere calculated by enclosing all individual
values of the independent experiments. Statistical significance
was proven by Student’s t test (two-tailed, unpaired) using the
GraphPad Prism 6 software. A p value of < 0.05 was consid-
ered statistically significant.
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Results
Sensitivity of melanoma cells to TRAIL and AdV-TRAIL
Previous in vitro investigations have shown that melanoma
cells have different sensitivity to TRAIL and TRAIL-armed
oncolytic viruses ranging from high sensitivity to nearly com-
plete resistance [24, 32, 33]. To investigate whether Mcl-1
silencing can overcome AdV-TRAIL resistance, we initially
examined four melanoma cell lines (MeWo,Mel-2a, SK-Mel-
19, Mel-HO) for their sensitivity to TRAIL/AdV-TRAIL.
Soluble TRAIL was added to cells at a dose of 50 ng/ml and
AdV-TRAIL at a MOI of 5. The expression of TRAIL in
AdV-TRAIL is controlled by a Dox-inducible promoter
(Fig. 1A). Therefore, AdV-TRAIL-infected cells received
Dox to induce TRAIL expression or were left without Dox
to investigate the cells response in the absence of TRAIL.
Sensitivity of cells was determined by measuring cell viability
using a calcein-AM flow cytometry assay 48 h after treatment
with TRAIL or AdV-TRAIL. The cell line Mel-HO was sen-
sitive to soluble TRAIL, whereas MeWo was completely re-
sistant. Mel-2a showed low sensitivity to soluble TRAIL,
while SK-Mel-19 cells were more sensitive than Mel-2a cells
but less sensitive thanMel-HO cells (Fig. 1B). In all cell lines,
AdV-TRAIL reduced cell viability significantly stronger than
soluble TRAIL. Mel-HO cells were highly sensitive to AdV-
TRAIL, whereas SK-Mel-19 and Mel-2a were moderately
sensitive. The effects were already seen in the absence of
Dox but were more pronounced after induction of TRAIL
expression by addition of Dox, demonstrating that expression
of TRAIL enhances the cytotoxicity of AdV-TRAIL. In clear
contrast, the cytotoxicity of AdV-TRAIL in MeWo was only
weak, and in particular, there was no difference between Dox-
mediated TRAIL induction and no induction.
Because of the markedly different degree of sensitivity to
TRAIL and AdV-TRAIL, the sensitive cell line Mel-HO, as
well as the resistant cell lineMeWo, were investigated further.
Efficient downregulation of Mcl-1 by siRNA
According to our previous data showing that silencing ofMcl-
1 sensitizes melanoma cell lines to TRAIL [34], we hypothe-
sized that Mcl-1 silencing may also increase the cytotoxicity
of AdV-TRAIL in melanoma cells. To investigate this, we
first sought the best conditions for silencing Mcl-1 in the cell
lines MeWo and Mel-HO. The cell lines were transiently
transfected with 15 to 100 nM of a siRNA directed against
Mcl-1 (siMcl-1) [27], and Mcl-1 protein levels were deter-
mined by Western blot analysis 24 h later (Fig. 2A).
Complete ablation of Mcl-1 in Mel-HO and nearly complete
ablation in MeWo was seen already with the lowest siMcl-1
concentration of 15 nM. To investigate the Mcl-1 knockdown
over time, both cell lines were transiently transfected with 30
nM siMcl-1, and Mcl-1 expression was determined by
Western blotting up to 48 h later (Fig. 2B). A strong decrease
in Mcl-1 expression was seen in Mel-HO cells already 12 h
after siMcl-1 transfection, while almost complete downregu-
lation was found after 24 h. In MeWo, weak silencing was
seen 12 h after siMcl-1 transfection, whereas a nearly com-
plete knockdown was seen 48 h after transfection. To ensure
that Mcl-1 was strongly silenced in subsequent experiments,
siMcl-1 was used at a concentration of 30 nM, and cells were
incubated for 48 h before treatment with AdV-TRAIL.
Mcl-1 silencing remains without effect on expression
of adenoviral proteins and TRAIL as well as on
replication of AdV-TRAIL
Wenext examinedwhetherMcl-1 silencing affects the expres-
sion of TRAIL and adenoviral E1A, which is the central viral
regulator protein of adenoviral replication. In the previous
experiment, application of AdV-TRAIL at aMOI of 5 resulted
in strong induction of cell lysis within 48 h (Fig. 1B) making a
realistic measurement of TRAIL and E1A expression uncer-
tain under the same experimental conditions. Therefore, here,
we reduced the investigation time and the dose of AdV-
TRAIL when Mel-HO cells were infected. Both MeWo and
Mel-HO cells were first transfected with siMcl-1 for 48 h and
subsequently infected with AdV-TRAIL at a MOI of 5
(MeWo) or a MOI of 2 (Mel-HO) and expression of Mcl-1,
E1A, and TRAIL were examined by western blotting 24 h
later in the presence and in the absence of Dox (Fig. 3A, B,
Supplementary Figure S1), while, as expected, the expression
of TRAIL both in the cells and their supernatant was strongly
induced by Dox, surprisingly E1A expression was slightly
reduced in the presence of Dox. The reason is not clear. Dox
is known to be able to suppress the expression of cellular
transcription factors [35] and a similar mechanism may be
involved in suppression of adenoviral E1A. TRAIL was also
detected at low levels in the absence of Dox, which indicates
some leakiness of the Dox-inducible promoter. Cellular Mcl-1
expression remained unaffected in AdV-TRAIL-infected
MeWo cells, whereas we observed strong Mcl-1 downregula-
tion in AdV-TRAIL-infected Mel-HO cells when TRAIL was
induced by Dox. Transfection with siMcl-1 resulted in strong
inhibition of cellular Mcl-1 expression in AdV-TRAIL-
infected MeWo cells and nearly complete ablation of Mcl-1
expression in AdV-TRAIL-infected Mel-HO cells.
Furthermore, silencing of Mcl-1 had no significant effect on
the expression of adenoviral E1A and TRAIL expression, as
compared to cells transfected with siCon (Fig. 3A).
We next examined virus replication in siMcl-1-transfected
and AdV-TRAIL-infected MeWo and Mel-HO cells. AdV-
TRAIL was administered at a MOI of 2 in each cell line,
and the levels of replicating virus were determined by
real-time PCR. The virus levels of AdV-TRAIL were
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higher in Mel-HO cells than in MeWo cells (1 × 106
virus genome copies/ml vs. 7 × 104 virus genome
copies/ml), but remained unaffected by Mcl-1 silencing
and/or TRAIL expression (Fig. 3B).
These results demonstrate that Mcl-1 silencing did not af-
fect AdV-TRAIL replication nor virus-mediated TRAIL ex-
pression in either cell line. The results also show that AdV-
TRAIL downregulates Mcl-1, but only in Mel-HO cells after
induction of TRAIL by Dox.
Mcl-1 silencing increases cytolytic activity of AdV-
TRAIL in TRAIL-resistant melanoma cells
To investigate, whether Mcl-1 silencing increases the cytolyt-
ic activity of AdV-TRAIL, we transfected MeWo and Mel-
HO cells with siMcl-1 or siCon. After 48 h, cells were infected
with AdV-TRAIL at a MOI of 2 (Mel–HO) or 25 (MeWo).
We increased the AdV-TRAIL dose for infection of MeWo in
this experiment as an initial experiment showed that effects of
Mcl-1 silencing were significant but weak using a MOI of 5
(Supplementary Figure S2A, B). Cell viability was deter-
mined by flow cytometry after calcein-AM staining at 24 h
and 48 h after infection. Already Mcl-1 silencing alone result-
ed in a reduction of cell viability down to 80% inMel-HO and
down to 72 % in MeWo at 48 h (Fig. 4A). Infection of MeWo
cells with AdV-TRAIL reduced the viability to 50% in the
absence of Dox and to 42%, when TRAIL was induced by
Dox after 48 h (Fig. 4A). The further increase of cell toxicity
by addition of Dox seems to result from high expression levels
of TRAIL induced by use of anMOI of 25 of AdV-TRAIL, as
Dox application had no effect on cell viability when AdV-
TRAIL was used at an MOI of 5 (Fig. 1B, Supplementary
Figure S2A). In Mel-HO, the effects of AdV-TRAIL on cell
viability were even more pronounced. Only 8% of Mel-HO
cells remained alive at 48 h after infection with AdV-TRAIL.
This percentage was further decreased to 4% when TRAIL
was induced by Dox (Fig. 4A). Silencing of Mcl-1 in AdV-
TRAIL-infected cells resulted in significantly enhanced cyto-
toxicity of AdV-TRAIL. In MeWo, cell viability dropped to
25 % and in Mel-HO to 5 % in the absence of Dox 48 h after
infection (Fig. 4A, B). After induction of TRAIL by Dox, cell
viability significantly decreased further to 12% in MeWo and
to 3% in Mel-HO (Fig. 4A, B). Cell killing assays confirmed
the loss of cell viability by the treatments (Fig. 4C). Based on
the data from Fig. 4A, we calculated the relative increase of
cytotoxicity mediated by Mcl-1 silencing in AdV-TRAIL-
infectedmelanoma cells withDox-induced TRAIL expression
48 h after application of the virus. Co-silencing of Mcl-1 in-
creased the loss of viability by 71% inMeWo but only by 36%
in Mel-HO cells compared to treatment with AdV-TRAIL
alone.
These results indicate that in both cell lines cytotoxicity of
AdV-TRAIL can be strongly enhanced by co-silencing of
Mcl-1. However, in relative terms, this effect was distinctly
stronger in MeWo than in Mel-HO cells.
Mcl-1 silencing increases apoptosis induction by AdV-
TRAIL in TRAIL-resistant melanoma cells
To determine whether the increase of cytotoxicity of AdV-
TRAIL by Mcl-1 silencing was caused by an increase in ap-
optosis induction, the number of apoptotic cells in MeWo and
Mel-HO cells was determined by cell cycle analysis after
propidium iodide staining and flow cytometry. Cells were
Fig. 2 Efficient downregulation ofMcl-1 byMcl-1 siRNAs in melanoma
cells. Western blot analyses of Mcl-1 in melanoma cell lines MeWo and
Mel-HO transfected with a siRNA targeting Mcl-1 (siMcl-1). A The
levels of Mcl-1 were assessed 24 h after transfection with different con-
centrations of siMcl-1. B Cells were transfected with 30 nM siMcl-1 and
Mcl-1 levels were analyzed after the indicated periods of time. Per lane,
30 μg protein were loaded and consistent blotting was proven by β-actin
staining. Experiments were performed twice and gave very similar results
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treated in the same way as for the determination of cell viabil-
ity. In untreated control cells, the number of apoptotic cells
was 1%. Merely silencing Mcl-1 significantly increased apo-
ptosis in both cell lines, with a slightly stronger effect in the
MeWo. Nonetheless, the number of apoptotic cells did not
exceed 10% (Fig. 5A). Also, treatment of MeWo cells with
AdV-TRAIL increased the number of apoptotic cells, but the
percentage of apoptotic cells remained below 15% (Fig. 5A,
B), and even after induction of TRAIL by Dox, the percentage
increased only up to 24% (Fig. 5A, B). In Mel-HO cells, the
percentage of apoptotic cells was distinctly higher after infec-
tion with AdV-TRAIL. In the uninduced state up to 33% and
after induction of TRAIL by Dox up to 41% of the cells were
apoptotic (Fig. 5A, B). Silencing of Mcl-1 significantly in-
creased apoptosis induction in AdV-TRAIL-infected MeWo
andMel-HO cells. InMeWo cells, the percentage of apoptotic
Fig. 3 AdV-TRAIL replication and expression of E1AΔpRb and TRAIL
in melanoma cells. A Western blot analyses of E1AΔpRb, TRAIL, and
Mcl-1 in the melanoma cell lines MeWo and Mel-HO. The cells were
transfected with 30 nM of a control siRNA (siCon) or siMcl-1 and infect-
ed 48 h later with AdV-TRAIL at a MOI of 5 (MeWo) and 2 (Mel-HO).
Simultaneously, TRAIL expression was induced by Dox as indicated.
Proteins were extracted 24 h after infection and expression of Mcl-1,
TRAIL, and E1AΔpRb was determined. As an internal loading control,
β-actin was used. Representative data from three independent experi-
ments are shown. B For detection of TRAIL in the supernatant the same
Western blot assay was repeated. Supernatant was collected 24 h after
infection, concentrated and the expression of TRAIL was determined.
Representative data from two independent experiments are shown. C
Replication of AdV-TRAIL. To measure viral replication of AdV-
TRAILMeWo andMel-HO cells were treated as described above, except
both cell lines were infected with AdV-TRAIL at aMOI of 2. To quantify
genome copy numbers of infectious virus particles, the cells were lysed
24 h after viral infection by freeze–thaw cycles, centrifuged and the su-
pernatant used for infection of HEK293 cells for 2 h. After washing, the
cells were lysed and the amount of viral DNAwas quantified by real-time
PCR. Presented are the mean genome copy numbers ± SEM of three
independent experiments
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Fig. 4 Viability of melanoma cells after treatment with AdV-TRAIL and
siMcl-1. A Viability of MeWo and Mel-HO cells after treatment with
AdV-TRAIL and siMcl-1.MeWo andMe-HO cells were transfected with
30 nM of siMcl-1 or siCon and infected 48 h later with AdV-TRAIL at a
MOI of 25 (MeWo) or 2 (Mel-HO). TRAIL expression was induced by
Dox as indicated. Cell viability was determined by calcein-AM staining
and flow cytometry 24 h and 48 h after infection with AdV-TRAIL. Data
are expressed as mean percentages of calcein-AM-positive cells (viable)
± SEM of three independent experiments. Statistical significance: *p <
0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. B The histograms
show the amount of viable and dead cells in the indicated samples.CCell
killing assays of Mel-HO and MeWo melanoma cell lines. Cells were
treated as described in A and crystal violet staining of attached cells was
performed at 48 h (MeWo) and 24 h (Mel-HO) after transduction with
AdV-TRAIL
Fig. 5 Apoptosis induction and caspase-3 activation in melanoma cells
treated with AdV-TRAIL and siMcl-1. A Apoptosis induction in MeWo
and Mel-HO cells after treatment with AdV-TRAIL and siMcl-1. Cells
were treated as described in Fig. 4. Apoptosis was determined by
propidium iodide staining and flow cytometry at 24 h and 48 h after
transduction with AdV-TRAIL. The mean percentages of sub-G1
(apoptotic) cells ± SEMs of three independent experiments are shown.
Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001.B The histograms show the amount of apoptotic sub-diploid (sub-
G1) cells as well as cells in cell cycle phases gap 1 (G1), gap 2 (G2), and
synthesis (S) in the indicated samples. C Western blot analyses of
caspase-8 (Csp8), cleaved caspase-9 (cCsp9), and cleaved caspase-3
(cCsp3). Cells were treated as described above and protein levels were
examined 24 h after infection of the cells with AdV-TRAIL. Consistent
blottingwas verified byβ-actin staining. Representative data from at least
two independent experiments are shown
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cells increased to up to 32 and 39% and inMel-HO cells to up
to 44 and 58% in the uninduced and Dox-induced state, re-
spectively (Fig. 5A, B). Calculation of the average relative
increase of apoptotic cells mediated by Mcl-1 silencing in
AdV-TRAIL-infected melanoma cells with Dox-induced
TRAIL expression 48 h after application of the virus revealed
that co-silencing of Mcl-1 increased the percentage of apopto-
tic cells by 61% in MeWo but only by 31% in Mel-HO cells
compared to the sole AdV-TRAIL treatment.
These results indicate that Mcl-1 silencing increases apo-
ptosis in AdV-TRAIL-infected MeWo and Mel-HO cells.
However, in relative terms, the induction of apoptosis was
distinctly higher in MeWo than in Mel-HO cells.
Silencing of Mcl-1 enhances caspase-3 activation in
AdV-TRAIL-transduced TRAIL-resistant melanoma
cells
In order to elucidate the mechanisms responsible for increased
apoptosis induction in MeWo and Mel-HO cells after Mcl-1
silencing and AdV-TRAIL infection, the activation of the initia-
tor caspase-8, the intrinsic initiator caspase-9, and the main ef-
fector caspase-3 were examined by western blot analysis 24 h
after application of AdV-TRAIL. Following silencing of Mcl-1,
no activation of caspase-3, caspase-8, or caspase-9 was detected.
In contrast, as seen by detection of the 43, 41, and 18 kDa cleav-
age products of caspase-8, 35 kDa cleavage product of caspase-
9, and 17 kDa cleavage product of caspase-3, there was strong
activation of the respective caspases in Mel-HO cells after infec-
tion with AdV-TRAIL and induction of TRAIL expression by
Dox (Fig. 5C, Supplementary Figure S1). Caspase-8 was also
activated in Mel-HO cells when TRAIL expression was not in-
duced (Fig. 5C, Supplementary Figure S1), suggesting that the
leaky expression of TRAIL in the uninduced state (Fig. 3A) was
sufficient to activate caspase-8. Silencing of Mcl-1 in AdV-
TRAIL-treated Mel-HO cells led to a distinctly stronger activa-
tion of caspase-3, but not of caspase-8 and caspase-9. This effect
was seen not only when TRAIL expression was induced by Dox
but also when TRAIL expression was not induced. Here again,
leaky TRAIL expression may contribute to the latter result.
Similar to Mel-HO cells caspase-8 was activated in MeWo cells
after infection with AdV-TRAIL due to leaky expression of
TRAIL in the uninduced state (Fig. 3A) and more prominently
after full induction of TRAIL expression by Dox (Fig. 5C,
Supplementary Figure S1). However, in MeWo cells, activation
of caspase-3 and weak activation of caspase-9 were only ob-
served in AdV-TRAIL-infected cells with induced TRAIL ex-
pression when Mcl-1 was silenced.
These results indicate that Mcl-1 silencing enhances
the activation of caspase-3 in AdV-TRAIL-infected
cells, in particular when the expression of TRAIL was
induced by Dox.
Silencing of Mcl-1 enhances AdV-TRAIL-mediated ne-
crosis in TRAIL-resistant melanoma cells
To determine whether the induction of necrosis may also con-
tribute to the increase of cytotoxicity of AdV-TRAIL by Mcl-
1 silencing, we next measured LDH release of MeWo and
Mel-HO cells. In untreated cells, LDH release was below
5%, whereas silencing of Mcl-1 significantly increased LDH
release, of both MeWo and Mel-HO cells (Fig. 6).
Nevertheless, LDH release caused by Mcl-1 silencing did
not exceed 11% in either cell line. Treatment of MeWo cells
with AdV-TRAIL increased LDH release up to 18% and in-
duction of TRAIL expression by Dox further increased LDH
release up to 25%. In Mel-HO cells, administration of AdV-
TRAIL resulted in a LDH release of 12 and 21% in the
uninduced state and after induction of TRAIL by Dox, respec-
tively. Silencing of Mcl-1 in AdV-TRAIL-infected MeWo
and Mel-HO cells significantly increased LDH release in both
cell lines to up to 26 and 34% in MeWo cells and to up to 20
and 25% in Mel-HO cells in the uninduced and Dox-induced
state, respectively (Fig. 6).
These results indicate that necrosis induction induced by
AdV-TRAIL is enhanced by silencing of Mcl-1.
Discussion
Here, we show that cytotoxicity of the TRAIL-expressing
oncolytic adenovirus AdV-TRAIL can be significantly im-
proved in TRAIL-resistant and TRAIL-sensitive melanoma
cell lines by silencing of the antiapoptotic Bcl-2 protein
Mcl-1. Moreover, our investigations revealed enhanced in-
duction of apoptosis via activation of caspase-3 as the primary
mechanism contributing to the increased cytotoxicity of AdV-
TRAIL by Mcl-1 silencing.
Although new treatments have improved overall survival
rates of patients with melanoma, current therapies have not
changed the fact that melanoma remains the major cause of
skin cancer-related deaths [36]. Hence, new strategies to ef-
fectively combat melanoma are required. A promising new
concept is represented by oncolytic viruses that selectively
replicate in and destroy tumor cells. To improve the efficiency
of oncolytic viruses, they can be equipped with death-
promoting transgenes. In this regard, we showed that arming
an oncolytic adenovirus with Dox-inducible expression of the
death ligand TRAIL (AdV-TRAIL) selectively induced apo-
ptosis in melanoma cells and significantly enhanced its anti-
tumor efficiency [24]. However, therapeutic use of AdV-
TRAIL is limited, as melanoma cells can be resistant to
TRAIL [24, 37]. Consistent with this, we found here that
AdV-TRAIL was highly cytotoxic in the TRAIL-sensitive
melanoma cell line Mel-HO but was not very effective in the
TRAIL-resistant melanoma cell l ine MeWo. Low
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susceptibility of the extrinsic apoptosis pathway for activation
by TRAIL seems to play a central role for inability of TRAIL
to kill melanoma cells. Therefore, activation of intrinsic apo-
ptosis pathway is of particular importance. This pathway,
however, is controlled by antiapoptotic Bcl-2 proteins, among
them Mcl-1, which is a key regulator of antiapoptotic,
prosurvival signaling in cancer cells. Mcl-1 was highly
expressed in MeWo and Mel-HO cells and silencing it signif-
icantly increased AdV-TRAIL-induced cytotoxicity and made
both AdV-TRAIL-infected melanoma cell lines more sensi-
tive to TRAIL-induced apoptosis. Interestingly, these effects
were also observed inMel-HO, although in this cell lineMcl-1
was already strongly downregulated after infection with AdV-
TRAIL and induction of TRAIL. The latter may be explained
by the sensitivity of this cell line to TRAIL, as it has been
shown that Mcl-1 can be cleaved at two aspartic acid residues
(Asp127 and Asp157) by caspase-3, which itself is activated
by TRAIL [38]. In accordance with this, caspase-3 was selec-
tively upregulated inMel-HO after AdV-TRAIL infection and
induction of TRAIL by Dox. Our finding may be of impor-
tance for treatment of melanomas, as they demonstrate that
silencing of Mcl-1 cannot only increase the cytotoxicity of
the AdV-TRAIL in TRAIL-resistant melanoma cells but also
in TRAIL-sensitive melanoma cells, even when Mcl-1 is
expressed at a very low level.
Regarding the strength of the increase in cytotoxicity in-
duced in AdV-TRAIL-infected melanoma cells after si-
lencing of Mcl-1, this was more pronounced in MeWo
than in Mel-HO. This indicates that inhibition of Mcl-1
has a greater impact on AdV-TRAIL activity when the
melanoma cells are resistant to TRAIL. In accordance
with this observation, we found that Mcl-1 knockdown
Fig. 6 Necrosis induction in melanoma cells treated with AdV-TRAIL
and siMcl-1. MeWo andMel-HO cells were treated as described in Fig. 4.
Lactate dehydrogenase (LDH) release was detected at 24 h and 48 h after
infection with AdV-TRAIL. Cytotoxicity values are given as percentage
of LDH values after complete cell lysis. Presented are the mean percent-
ages of LDH release ± SEM of three independent experiments. Statistical
significance: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
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had a stronger effect on apoptosis induction in AdV-
TRAIL-infected MeWo compared to Mel-HO. Less sus-
ceptibility of Mel-HO may be explained by the fact that
in this cell line, induction of apoptosis by the TRAIL-
mediated extrinsic apoptosis pathway is already effective
and a further increase in apoptosis by enhanced activa-
tion of the intrinsic apoptosis pathway may therefore be
limited. In contrast, in TRAIL-resistant MeWo, apopto-
sis is only weakly induced via the TRAIL-mediated ex-
trinsic pathway. Therefore, the removal of inhibitors of
the intrinsic apoptosis pathway, as demonstrated here by
silencing of Mcl-1, has greater effects on apoptosis
induction.
Oncolytic adenoviruses usually kill tumor cells by necrosis-
like cell death, which is independent of the basic apoptosis ma-
chinery of the infected cell [39]. Confirming this fact, we found
in both cell lines AdV-TRAIL induced necrosis, even in the
absence TRAIL induction. Interestingly, induction of TRAIL
by Dox in AdV-TRAIL-infected MeWo and Mel-HO cells re-
sulted in increased necrosis. Moreover, when AdV-TRAIL was
combined with Mcl-1 silencing, a further significant increase of
necrosis was detected. Previously, it has been shown in tumor
cells that TRAIL can also induce necrosis via necroptosis [40].
Necroptosis describes a programmed form of necrosis, which is
induced by activation of a signal cascade that involves the
serine–threonine receptor interacting protein (RIP) kinases
RIPK1 and RIPK3 [41, 42]. Induction of necroptosis is indepen-
dent of caspase-activated apoptosis but can effectively be
prevented by caspase-8. Even non-stimulated caspase-8 is suffi-
cient for the suppression of programmed necrosis [43].We found
strong activation of caspase-8 in AdV-TRAIL-infected cells.
Therefore, most likely secondary necrosis and not necroptosis
is the basic mechanism leading to increased necrosis caused by
TRAIL expression as well as by Mcl-1 silencing in AdV-
TRAIL-infected melanoma cells.
We also investigated whether there is an induction of reactive
oxygen species (ROS) following AdV-TRAIL and Mcl-1 treat-
ment in bothMeWo andMel-HO cells. However, there were not
any significant changes of ROS levels in response to AdV-
TRAIL or siMcl-1 treatment (results not shown). Thus, induction
of ROS does not appear as relevant for the effects of AdV-
TRAIL or siMcl-1 described here in melanoma cells.
Increasing the cytotoxicity of AdV-TRAIL by silencing of
Mcl-1 may have relevance for further employment of the virus
in melanoma therapy. In particular, the effectiveness and the
safety of our approach must now be confirmed in vivo. In the
last few years, several small molecules have been developed
which efficiently inhibit Mcl-1 in vivo [44, 45]. However, a
clinical phase I dose-escalation study for treatment of multiple
myeloma, non-Hodgkin lymphoma, or acute myeloid leuke-
mia by the Mcl-1 inhibitor AMG 397 was terminated due to
cardiac toxicity. It has been shown that Mcl-1 plays a crucial
role in the survival of hematopoietic stem cells, lymphocytes
and cardiomyocytes [46–48]. Thus, inhibition of Mcl-1 in
normal cells by small molecule inhibitors may be the cause
for the observed side effects. Such side effects could be
avoided by tumor cell-specific inhibition of Mcl-1, for exam-
ple by RNA interference-mediated silencing of Mcl-1. In this
regard, we found that transiently expressed miR-193b [34] as
well as anti-Mcl-1 artificial microRNAs and small hairpin
RNAs are able to suppress Mcl-1 in melanoma cells (results
not shown). These small regulatory RNAs can be easily
inserted into the genome of AdV-TRAIL, in order to enable
their melanoma cell-specific delivery and silencing of Mcl-1.
In conclusion, we show here that cytotoxicity of AdV-
TRAIL can be enhanced in TRAIL-resistant and TRAIL-
sensitive melanoma cells by co-silencing of the antiapoptotic
Bcl-2 protein Mcl-1 by activation of apoptosis and necrosis.
Targeting of Mcl-1 may therefore contribute to a more effec-
tive treatment of melanoma using TRAIL-expressing
oncolytic adenovirus.
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